<DOC>
	<DOCNO>NCT00502996</DOCNO>
	<brief_summary>This single arm study assess safety MabThera plus methotrexate patient rheumatoid arthritis lack response 1-5 DMARDs biological agent . Patients receive MabThera ( 1g i.v . ) day 1 15 , concomitantly methotrexate &gt; =15mg p.o./week . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Non-Comparative Study Assess Safety MabThera ( Rituximab ) Patients With Rheumatoid Arthritis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; rheumatoid arthritis &gt; =6 month ; lack response 15 DMARDs biological agent ; rheumatoid factor positive . chronic inflammatory articular disease systemic rheumatic disease ; joint bone surgery 8 week prior randomization ; previous treatment celldepleting therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>